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T lymphocytes play a critical role in host defense in all anatomical sites including mucosal
surfaces. This not only includes the effector arm of the immune system, but also regu-
lation of immune responses in order to prevent autoimmunity. Genetic targeting of PI3K
isoforms suggests that generation of PI(3,4,5)P3 by PI3K plays a critical role in promoting
effector T cell responses. Consequently, the 5′- and 3′-inositol poly-phosphatases SHIP1,
SHIP2, and phosphatase and tensin homolog capable of targeting PI(3,4,5)P3 are poten-
tial genetic determinants of T cell effector functions in vivo. In addition, the 5′-inositol
poly-phosphatases SHIP1 and 2 can shunt PI(3,4,5)P3 to the rare but potent signaling
phosphoinositide species PI(3,4)P2 and thus these SHIP1/2, and the INPP4A/B enzymes
that deplete PI(3,4)P2 may have precise roles inT cell biology to amplify or inhibit effectors
of PI3K signaling that are selectively recruited to and activated by PI(3,4)P2. Here we sum-
marize recent genetic and chemical evidence that indicates the inositol poly-phosphatases
have important roles in both the effector and regulatory functions of the T cell compart-
ment. In addition, we will discuss future genetic studies that might be undertaken to further
elaborate the role of these enzymes in T cell biology as well as potential pharmaceutical
manipulation of these enzymes for therapeutic purposes in disease settings where T cell
function is a key in vivo target.
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INTRODUCTION
Inositol phospholipid signaling pathway plays an integral role in
development, proliferation, differentiation, and survival of lym-
phocytes (1–4). The principal second messenger of the PI3K
pathway PtdIns(3,4,5)P3 is generated by phosphorylation of the 3′-
hydroxyl group of PtdIns(4,5)P2 by PI3Ks. PI3Ks are grouped into
three categories, Class I, II, and III on the basis of substrate speci-
ficity and structure. Only class I PI3Ks can use PtdIns(4,5)P2 to
generate PtdIns(3,4,5)P3 at the inner leaflet of plasma membrane
(5). PtdIns(3,4,5)P3 acts as binding site for several intracellu-
lar signaling molecules that containing a Pleckstrin-homology
domain (PH-domain) and thus facilitates their recruitment to the
plasma membrane. AKT/PKB is the most important PH-domain
containing kinase required for cell growth, survival, and prolif-
eration in most cell types and appropriately its PH-domain can
bind PtdIns(3,4,5)P3 (6, 7). In addition to AKT, the PH-domain
containing Tec family tyrosine kinases ITK (IL-2-inducible T cell
kinase) and BTK (Bruton agammaglobulinemia tyrosine kinase)
also have specificity for PtdIns(3,4,5)P3 and are important medi-
ators of PI3K signaling pathway in T and B cells, respectively
(Figure 1). Based on genetic models both class IA (p110α, p110β,
and p110δ) and class IB PI3K (p110γ) play roles in thymocyte
development. p110γ-knockout mice have increased apoptosis of
DP thymocytes and double knockout p110δ/γ mice have sig-
nificantly reduced number of thymocytes, a profound T cell
lymphopenia and multiple organ inflammation (8–12). In addi-
tion to that mice with a knock-in point mutation of p110δ
(p110deltaD910A/D910A) have severe defects in T cell receptor
signaling and impaired Treg cell function (13–15). The T cell spe-
cific class IA PI3K deficient mice do not have defects in thymocyte
and in peripheral T cell development, but they do exhibit defective
TCR signaling, in vitro proliferation and cytokine production (16,
17). Altogether these findings demonstrate that the PI3K signal-
ing pathway responsible for generation of PtdIns(3,4,5)P3 plays
an important role in T cell development and activation and sug-
gest that inositol poly-phosphatases like phosphatase and tensin
homolog (PTEN), SHIP1, SHIP2, and INPP4A/B may have an
opposing, or in some cases, a facilitating role downstream of PI3K
in T lymphocytes.
The cellular pool of inositol phospholipids is determined
in part by inositol phosphatases that by dephosphorylation
of PtdIns(3,4,5)P3, can regulate PI3K-mediated signaling path-
way. Three important phosphatases, which dephosphorylate
PtdIns(3,4,5)P3 are PTEN, SHIP1, and SHIP2. PTEN is 3′ poly-
phosphatase that converts PtdIns(3,4,5)P3 to PtdIns(4,5)P2 while
the SHIP family phosphatases, SHIP1 and SHIP2, are 5′ poly-
phosphatases, which convert PtdIns(3,4,5)P3 to PtdIns(3,4,)P2
(18, 19). The importance of these phosphatases in immune cell
signaling was revealed by the demonstration that SHIP1 deficiency
leads to severe myeloproliferative disorder and impaired NK cell
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FIGURE 1 | Phosphoinositide signaling and its regulation by
phosphatases. PI3K converts PI(4,5)P2 to a key secondary messenger
PI(3,4,5)P3. Phosphatases like PTEN and SHIP1/2 regulate cellular levels
of PI(3,4,5)P3 by hydrolyzing it to PI(4,5)P2 and PI (3,4)P2 respectively.
PLCγ converts PI(4,5)P2 to IP3 and DAG. IP3 a soluble inositol phosphate
is required for Ca2+ mobilization while DAG can activate the
Ras-Raf-ERK1/2 pathway. IP3 3-Kinases convert IP3 to IP4, another
important soluble inositol poly-phosphate that either positively or
negatively regulates the binding of PI(3,4,5)P3 to PH-domain containing
proteins. The SHIP1/2 product PI(3,4)P2 is hydrolyzed by INPP4A/B into
PI(3)P by removal of the phosphate at the 4-position of the inositol ring.
PI(3,4,5)P3 and/or PI(3,4)P2 enable recruitment to the plasma membrane
of several PH-domain containing proteins including PDK1, AKT, BTK, ITK,
and thus regulate pivotal cellular processes including activation,
proliferation, and survival. PH-domain containing adaptor proteins (GABs,
SKAPs, Bam32, and TAPP) can also bind to phosphoinositides and
regulate cell signaling (indicated as green boxes). AKT, Protein Kinase B;
PDK1, phosphoinositide-dependent kinase-1, PLCγ phospholipase Cγ;
ITK, IL-2-inducible T cell kinase) and BTK, Bruton agammaglobulinemia
tyrosine kinase.
function while mice with a conditional deletion of PTEN have
impaired T cell immune responses (20–22). The present review
focuses on the role of these inositol phosphatases in T cell biology.
SHIP1 IN T CELL BIOLOGY
SHIP1 (Src homology 2-containing inositol phosphatase) is a 5′-
inositol poly-phosphatase that removes the 5′ phosphate from
PtdIns(3,4,5)P3 and Ins(1,3,4,5)P4, thereby regulating PI3K sig-
naling pathway (23). SHIP1 is expressed in hematopoietic cells,
mesenchymal stem cells, and osteoblasts (24) as a 145/150 kDa
doublet. SHIP1 contains an N-terminal SH2 domain, a central
phosphatase domain, a C-terminal NPXY motifs, a Serine residue
that can be phosphorylated by PKA, proline rich sequences as well
as domains adjacent to the phosphatase domain that can recognize
either its substrate or its product (23). The SH2 domain mediates
binding of SHIP1 to ITAM and ITIM motifs in receptor tails such
as the CD3 chains that associate with the TCR (25, 26) or with
various adaptor proteins (27, 28). By virtue of its enzymatic as
well as its non-enzymatic functions, SHIP1 is implicated in various
signaling pathways related to proliferation, apoptosis, cytokine sig-
naling in lymphocytes and myeloid cells (23). Germline SHIP1−/−
mice although viable after weaning develop profound infiltration
of myeloid cells in the lungs and severe inflammation in the termi-
nal ileum of the gut resembling human Crohn’s disease (29) which
leads to their early demise (20, 30). SHIP1−/−mice have increased
number of myeloid cells in most of tissues, but are lymphopenic
(20) and have a profound deficit of T cells in the gut (29) indicat-
ing diverse functions for SHIP1 signaling in myeloid cells and T
lymphocytes.
SHIP1 IN T CELL SIGNALING
First demonstration of involvement SHIP1 in T cells came from
the observation that ligation of CD3 or CD28 on T cells results in
SHIP1 tyrosine phosphorylation and membrane re-localization
(31). SHIP1 is thought to be a component of a signaling com-
plex that includes LAT (linker for activation of T cells), Grb2,
Dok (downstream of tyrosine kinase) 1, and Dok2 that negatively
regulate TCR signaling (32). SHIP1 functions as an adaptor that
is required for tyrosine phosphorylation of Dok1 and Dok2 and
thus enables Dok1/2 anchoring to LAT to negatively regulate the
Zap-70 and AKT kinases thus attenuating TCR signaling (32).
Consistent with the proposed negative regulation of TCR signal-
ing, SHIP1 together with adaptor Dok1 and Dok2 has also been
shown to be associated with the CD4-mediated inhibitory signal-
ing (33). SHIP1 can also negatively regulate activation and mem-
brane localization of Tec Kinase, which plays an essential role in
PLCγ activation upon TCR stimulation (34, 35). However, despite
these biochemical studies suggesting SHIP1 limits TCR signaling
splenic T cells isolated from germline SHIP1−/− mice have defec-
tive TCR signaling as shown by their poor proliferation in response
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to TCR stimulation. In addition, SHIP1−/− T cells fail to induce
IL-2 and IFNγ upon PMA/ionomycin stimulation although they
have elevated levels of CD69 and CD25 and dramatically reduced
expression CD62L and CD45RB expression (36). However a T cell-
restrictive deletion of SHIP1 (CD4CreSHIP∆IPflox) that deletes
SHIP1 at double positive thymocyte stage does not exhibit the
same T cell phenotype observed in the germline SHIP1−/− mice
(37). SHIP1 deleted T cells in these mice do not regulate TCR
signal strength and no difference in the phosphorylation status of
AKT, ERK, Zap-70, PLCγ, or calcium influx was observed between
SHIP1−/− and WT T cells. Also, in contrast to the poor pro-
liferation of T cells from germline deficient mice, T cells from
CD4CreSHIP∆IPflox mice proliferate normally in response to TCR
stimulation. The authors argued that the observed phenotype of
T cells in germline SHIP1−/− mice is due to pleiotropic effect of
dysregulated immune system as a consequence of SHIP1-deficient
environment (37, 38). However, we and others have found that the
in-frame deletion strategy utilized still allows substantial expres-
sion of a near full-length version of SHIP1 that only lacks the
enzyme domain (39). Because of SHIP1’s ability to function in cell
signaling by masking binding sites on receptor tails for other regu-
latory kinases and phosphatases (40, 41) confounds interpretation
of results from SHIP∆IPflox strain difficult.
SHIP1 IN T CELL DEVELOPMENT
SHIP1 alone does not affect T cell development as no deficiencies
in the development of T cells in the thymus was observed in either
germline SHIP1−/− deficient mice or in CD4CreSHIP∆IPfloxmice
(20, 36, 37). However, a double knockout of SHIP1 and adaptor
protein Dok1 plays an important role in T cell development since
mice with combined deficiency of SHIP1 and Dok1 have signif-
icantly reduced total thymocyte numbers, percentage of CD4+
CD8+ double positive T cells and increased CD4−CD8− double
negative T cells (36).
SHIP1 has been shown to be required for both CD4+ and CD8+
T cell survival homeostasis at mucosal sites (29, 42). SHIP1−/−
mice develop spontaneous intestinal inflammation, the disease is
highly demarcated and confined to the terminal ileum, which
resembles classical human Crohn’s disease (29). The disease is
characterized by severe reduction in CD4+ and CD8+ T cells
in the lamina propria of SHIP1−/− mice suggesting that SHIP1
is required for effector T cell persistence in the small intestine.
Because T cells play an important role in normal immune sur-
veillance to both commensal microorganism and pathogens, in
their absence SHIP1-deficient Neutrophils and other myeloid
cells over-respond resulting in lethal inflammation in SHIP1−/−
mice (29). The mechanism of selective loss of T cells in mucosal
tissues is currently under investigation. T cell-restrictive SHIP1-
deficient CD4CreSHIP∆IPflox reported by Tarasenko et al. have
apparently no defect in T cell activation or T cell numbers in
periphery; however, mucosal T cells were not examined in their
report (37). Interestingly T cells from CD4CreSHIP∆IPflox mice
show biased toward Th1 skewing and have defective production
of Th2 cytokines IL-4, IL-5, and IL-13. Consistent with this T
cells from CD4CreSHIP∆IPflox mice respond poorly to in vivo
challenge to Schistosoma mansoni eggs, which normally induce
a Th2 response. These cells also express elevated levels of T-bet
which has been shown to regulate CD8 T cell function. Consis-
tent with that CD8 T cells from CD4CreSHIP∆IPflox mice that also
delete SHIP1 in CD8 T cells were more efficient in a cytotoxicity
assay as compared to WT controls (37).
REGULATION OF Tregs AND TH17 CELLS BY SHIP1
SHIP1 has been shown to limit expansion both myeloid and T
lymphoid immune-regulatory cell (30, 36, 43–46). Peripheral T
cells from SHIP1−/− mice have significantly increased numbers
of CD4+CD25+FoxP3+ conventional regulatory T cells (36, 45).
They exhibit significantly higher levels of CD103, GITR, OX40,
and FcRγII/III, which is associated with their regulatory func-
tion (45). SHIP1−/− regulatory T cells are equally suppressive
both in vitro and in vivo when compared to SHIP1-competent
T regulatory cells (45). In addition to conventional regulatory
T cells, SHIP1 deficiency also promotes the accumulation of
CD4+CD25− iTreg cells that express FoxP3 in the periphery that
have suppressive function (45). Although SHIP1 deficiency seems
to promote regulatory T cell expansion, the inflammatory envi-
ronment brought about by SHIP1-deficient myeloid cells may also
play a role in Treg cell development. An elegant study by Collazo
et al. demonstrated that SHIP1 regulates Treg cell development
and iTreg formation in both a T cell intrinsic and extrinsic man-
ner. Both T cell specific deletion of SHIP1 in LckCreSHIPflox/flox or
myeloid cell-specific deletion in LysCreSHIPflox/flox mice increased
the peripheral pool of CD4+CD25+FoxP3+ regulatory T cells
and CD4+CD25− iTreg cells expressing FoxP3 (44). These results
indicate that SHIP1 exerts both T cell intrinsic and extrinsic
control over peripheral Treg cell development and conversion
in the periphery. In contrast to this, Tarasenko et al. in the
CD4CreSHIP∆IPflox model reported that SHIP1 deletion had no
effect on Treg cell development. However, the concern noted
above regarding residual expression of a near full-length SHIP1
mutant in SHIP∆IPflox mice hampers interpretation of this neg-
ative finding. Locke et al. also reported T cell-intrinsic function
of SHIP1 in iTreg development. They showed that the ability
of SHIP1−/− CD4+CD25−CD45RBhigh T cells to develop into
Foxp3+ cells in vitro in presence of TGFβ alone or in combina-
tion with retinoic acid (RA) was much higher compared to WT
T cells (47). Interestingly, FoxP3 can enhance the expression of
miR-155 by binding to an intron within the DNA sequence of
the miR-155 precursor RNA suggesting that FoxP3 could poten-
tially maintain Treg numbers by suppressing SHIP1 expression
through induction of miR-155 (48–50). Altogether the above stud-
ies suggest a potent role for SHIP1 in T cell-intrinsic control
of native Treg development and iTreg formation in the periph-
ery. In contrast to SHIP1’s function in limiting Treg numbers, it
has been shown to required for Th17 development. SHIP1−/− T
cells fail to differentiate into Th17 cells and this deficiency was
accompanied by reduced IL-6 mediated phosphorylation STAT3
(47). SHIP1−/− T cells have high basal level of T-bet, a transcrip-
tion factor known to negatively regulate Th17 differentiation and
lower levels of RORγt mRNA, and thus it is likely that the altered
T cell differentiation are regulated by SHIP1 via its control of
these transcription factors at the molecular level. Table 1 sum-
marizes the function SHIP1 in T cells in different genetic mouse
models.
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Table 1 |T cell phenotypes of inositol poly-phosphatase mutant mice.
No. KO Gene deletion T cell phenotype Reference
1 SHIP−/− Germline SHIP1 deletion Poor proliferation of T cells Helgason et al. (20), Kerr
et al. (29), Kashiwada et
al. (36), Collazo et al.(45)
Elevated levels of CD69, CD25 on T cells, and reduced
levels of CD69L, CD45RB
Increased CD4+CD25+FoxP3+ Tregs
Increased CD4+CD25−FoxP3+ iTregs
Reduced CD4+ and CD8+ T cells in the gut
2 SHIP−/−DOK1−/− Germline SHIP1 and DOK1 deletion Reduced thymocytes Kashiwada et al. (36)
Reduced CD+CD8+T cells in thymus
Reduced CD8+ T cells in the spleen
Altered CD4:CD8 ratio
Increased CD4+CD25+FoxP3+ Tregs
3 CD4CreSHIPf/f SHIP1 deletion in T cells Normal T cell development Tarasenko et al. (37)
No defect in T cell activation
Reduced levels of TH2 cytokines IL-4, IL-5, and IL-13
CD8+ T cells are more cytotoxic
4 LckCreSHIPf/f SHIP1 deletion in T cells Increased CD4+CD25+FoxP3+ Tregs Collazo et al. (44)
Increased CD4+CD25−FoxP3+ iTregs
5 LysCreSHIPf/f SHIP1 deletion in myeloid cells Increased CD4+CD25+FoxP3+ Tregs Collazo et al. (44)
Increased CD4+CD25−FoxP3+ iTregs
6 PTEN−/+ Heterozygous deletion of PTEN Increased proliferation of T cells Di Cristofano et al. (51)
Reduced AICD
7 LckCre-PTENflox/− PTEN deletion in T cells/heterozygous
deletion of PTEN other tissues
CD4+ T cell lymphoma Suzuki et al. (22)
Defect in thymic negative selection
Increased TH1/TH2 cytokines
T cells are resistant to apoptosis
8 LckCre-PTENf/f PTEN deletion in T cells T cells are hyper-responsive to TCR stimulation Hagenbeek et al.(52),
Walsh et al.(53)Refracted to anergy induction
Reduced expansion of Tregs
Increased TH2 cytokine
9 OX40crePTENflox PTEN deletion in mature CD4+T cells T cells are hyper-proliferative Soond et al. (54)
Secrete more cytokine
T cells are super-helper with enhanced inflammatory
antibacterial and anti-tumor responses
SHIP1 IN T CELL MIGRATION
PI3K-associated pathways have been implicated in regulation of
chemokine signaling and migration of cell toward chemokine gra-
dient (55, 56). In a polarized plasma membrane PI3K accumulates
at the leading edge of the migratory cells leading to localized
production of PI(3,4,5)P3 and thereby regulating cell migration.
Because SHIP1 regulates levels of PI(3,4,5)P3 at PI3K signaling
complexes it stands to reason that it may then regulate chemo-
taxis. Nishio et al. demonstrated that SHIP1-deficient neutrophils
fail to polarize PI(3,4,5)P3 at the leading edge of migrating cells
resulting in the inefficient migration of neutrophils and reduced
polarity in response to chemoattractants (57). In T cells enhanced
chemotaxis in response to stromal cell-derived factor-1 (SDF1)
has been reported with SHIP1−/− thymocytes and splenic CD4+
T cells (58). Consistent with this enforced overexpression of SHIP1
in Jurkat T cells abrogated CXCL12 mediated chemotaxis by this
cell line (59). However it was also shown that the chemotaxis of
SHIP1−/− lymphocytes with other chemokines was comparable
with that of WT lymphocytes indicating that SHIP1 involvement
in regulating chemotaxis may be chemokine specific (58). More
recently Harris et al. by using a lentivirally expressed SHIP1-
specific shRNA in human CD4+ T cells showed that although
the directional chemotaxis toward CXCL11 was unaffected, the
overall basic motility and morphology of T cells was impaired
in SHIP1 knockdown (KD) primary human T cells (60). SHIP1
KD T cells exhibited increased actin polymerization and loss of
microvilli projection upon stimulation with CXCL11. Formation
of microvilli involves phosphorylation of ezrin/radixin/moesin
(ERM) proteins and once the cell is activated microvilli are fre-
quently lost due to Rac-mediated dephosphorylation of ERM
Frontiers in Immunology | T Cell Biology September 2013 | Volume 4 | Article 288 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Srivastava et al. Inositol poly-phosphatases in T cell biology and disease
proteins (61). SHIP1 seems to negatively regulate Rac activation
and/or ERM phosphorylation through a non-catalytic function
as pretreatment with the PI3K inhibitor Ly294002 fails to res-
cue microvilli disassembly (60). However, a partial rescue in ERM
phosphorylation by a Rac inhibitor in SHIP1 KD T cells indicates
that Rac independent pathways are also involved. Additionally, the
PH-domain containing adaptor protein Bam32, that can bind to
both PI(3,4,5)P3 and PI(3,4)P2, the SHIP1 substrate and product,
respectively, is required for Rac1 activation and efficient BCR-
induced cell adhesion (62). Thus, it is possible that both SHIP1
catalytic and non-catalytic functions are required for chemotaxis
and cytoskeletal rearrangement; however, mechanistic studies in T
cell conditional SHIP1 mutants are required to better define spe-
cific functions of SHIP1 in regulating these processes in an in vivo
setting.
SHIP1 IN T CELL APOPTOSIS
The PI3K pathway is largely associated with cellular survival and
proliferation as its product PI(3,4,5)P3 is known to activate mol-
ecules required for cell survival and proliferation. Because SHIP1
degrades PI(3,4,5)P3, it is primarily considered a negative regu-
lator of PI3K-mediated cell survival. Indeed, SHIP1 plays a pro-
apoptotic function in myeloid, erythroid, and in some instances
B cells (63–66). However, it appears to play an opposite func-
tion in T cells. For instance SHIP1 limits Fas-induced apoptosis
in human primary T cells ex vivo and a leukemic T cell line (67).
Jurkat T cells, which do not express SHIP1 at normal levels are
very sensitive to FasL mediated apoptosis; however, when SHIP1
is over-expressed in Jurkat T cells they become resistant to H2O2
and FasL mediated apoptosis (67, 68). It is also reported that SHIP1
attenuates FcγRIIB mediated apoptosis in B cells and that the fail-
ure to recruit SHIP1 to the receptor results in enhanced apoptosis
(69, 70). Importantly SHIP1−/− mice are lymphopenic, and have
profound deficiency of both CD4+ and CD8+ T cells in the gut
indicating that SHIP1 might be required for T cell survival (20,
29). A selective deficiency of effector T cells at these sites might
result in recruitment of myeloid cells, which subsequently leads
to the lethal mucosal inflammation in both the lungs and gut
of SHIP1−/− mice (23, 29). Interestingly reconstitution of sub-
lethally irradiated SHIP1−/− mice with SHIP1-competent T cell
graft protects them from mucosal inflammation and prolongs their
survival. Moreover, SHIP1 is required for persistence of mature T
cells in the periphery and at mucosal surfaces as SHIP1−/− T cells
are impaired for survival when forced to compete with SHIP1+/+
T cells for representation in the peripheral T cell pool of either
immunocompetent or SCID hosts. Our preliminary studies indi-
cate that SHIP1 mediated protection of T cell death at mucosal
surfaces involves Fas-FasL death receptor pathway (42). Unlike
myeloid cells in which SHIP1 appears to promote cell death, T cells
require SHIP1 for their survival and persistence. A growing body
of evidence implicates PI(3,4)P2, the SHIP1 product, in cell sur-
vival as it can more efficiently recruit and activate Akt (71, 72) and
protects cancer cells from apoptosis induced by SHIP1 selective
(43) and pan-SHIP1/2 inhibitors (73). Consistent with this role of
PI(3,4)P2 and SHIP1/2 in promoting cell survival, increased levels
of PI(3,4)P2 in INPP4A and INPP4B mutant mice promote cell
transformation and tumorigenicity (74, 75). SHIP1 and SHIP2
should not only be considered terminators of PI3K-mediated sur-
vival pathway, but paradoxically also facilitators of such survival
signaling. With the growing evidence of its anti-apoptotic role in
T cells, and in various cancer cells, it is important to understand
when and how SHIP1 promotes pro-apoptotic vs. anti-apoptotic
signaling. Here both cell types and the involved receptor(s) are
likely critical determinants of this positive vs. negative role for
SHIP1 and SHIP2 in apoptosis.
SHIP1 AND PHOSPHOINOSITIDE-BINDING PH-DOMAIN
CONTAINING ADAPTOR PROTEINS
SHIP1’s role as a positive regulator of PI3K signaling pathway can
also be attributed to the ability of PI(3,4)P2, the SHIP1 product
to mediate recruitment of PH-domain containing adaptor pro-
teins including SKAP adaptors (SKAP55 and SKAP-hom), Bam32
(also known as DAPP1), TAPP1, and TAPP2 (76). These adap-
tor proteins have differential ability to bind phosphoinositides,
PI(3,4,5)P3 vs. PI(3,4)P2 (Figure 1) and also exhibit differential
expression across immune cell types. For instance SKAP55 expres-
sion is relatively more restricted to T cells while SKAP-hom is more
widely expressed in immune cells. Although Bam32 is restricted to
hematopoietic cells, it is more abundant in B cells and expressed
in lower levels in T cells, dendritic cells, and macrophages. TAPP
proteins are widely expressed in all the tissues; however TAPP2 is
more abundant in immune cells (76). TAPP1 and TAPP2 stand out
among the adaptor proteins as they can only bind to PI(3,4)P2 (27,
77), while SKAP adaptors and Bam32 can bind to both PI(3,4,5)P3
vs. PI(3,4)P2 with equal affinity (76). Mice deficient in SKAP55,
which predominantly functions in T cells have impaired TCR
induced adhesion to integrin ligands suggesting a role of SKAP
in PI3K-mediated integrin activation in lymphocytes (78). Bam32
has been implicated in BCR signaling of B cells as Bam32−/− mice
have defects in various aspects of B cell activation. Bam32−/− B
cells have impaired BCR-induced proliferation and defective T-
independent antibody responses (62). Bam32 has also shown to
be required for germinal center progression and antibody affinity
maturation (79). Bam32−/− B cells are defective in cell spread-
ing presumably due impaired cytoskeleton rearrangement (76). In
T cells Bam32 is required for TCR mediated ERK activation (80,
81). Thus, SHIP1 through hydrolysis of PI(3,4,5)P3 to PI(3,4)P2
could differentially regulate the recruitment of SKAP and Bam32
adaptors and thereby impact T cell signaling. This question merits
further study in SHIP mutant T cells and in the mice mutants for
these adaptor proteins.
SHIP1 has been shown to enhance membrane recruitment of
TAPP1 and TAPP2, the only adaptor proteins known to exclusively
bind PI(3,4)P2 (82). Recently a knock-in mouse model that express
normal endogenous level of mutant TAPP1 and TAPP2 which
are incapable of binding to PI(3,4)P3 has been made to under-
stand their physiological functions (83). Interestingly, the defects
observed in the B cells of TAPP KI mice showed remarkable simi-
larities with that of SHIP1−/− mice (84). TAPP KI mice have ele-
vated levels of serum immunoglobulin, autoantibody production,
and they show a lupus-like phenotype. Importantly AKT phos-
phorylation was significantly increased upon BCR cross linking in
B cells purified from these mice enhancing their proliferation (84).
This indicates that in the absence of TAPP adaptor proteins, the
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PI(3,4)P2 is available to promote AKT recruitment and resulting in
increased proliferation and survival, consistent with the proposed
positive function of SHIP1 in survival and proliferation (23). The
precise role(s) of TAPP as adaptor proteins in T cells is relatively
uncharacterized; however, TAPP can bind to PTPL1 which, has
been shown to inhibit cytokine-induced TH1/TH2 differentiation
(85). Therefore TAPP may potentially play a role in cytokine sig-
naling in T lymphocytes by promoting membrane localization or
activity of PTPL1. Although much is known about Bam32 and
TAPP’s function in B cells, it remains to determine whether there
is a physiological function for the adapters proteins that involves
T cell signaling.
SHIP1 AND SOLUBLE INOSITOL PHOSPHATE IP4
In addition to hydrolysis of PI(3,4,5)P3, SHIP1 can also dephos-
phorylate soluble inositol-1,3,4,5 tetrakisphosphate (IP4) in vitro
(18, 86). IP4 is generated by phosphorylation of Ins(1,4,5)P3 (IP3)
at its 3-position by IP3 3-Kinases (IP33K) (Figure 1). Mammals
express four IP3Ks; ItpkA/B/C and IPMK (IP multikinase). Lym-
phocytes predominantly express two Iptks, IptkB, and Iptkc, while
IptkC is expressed in many tissues, expression of IptkB is restricted
to hematopoietic cells and brain (2, 87). IP4 is required for T cell
development as Itpkb−/−mice, are severely immunocompromised
and lack mature T cells because of a block at the CD4+CD8+
DP stage due to impaired positive selection in the thymus (88,
89). Interestingly, PLCγ mediated DAG-induced ERK activation
which is essential for positive selection is profoundly impaired in
Itpkb−/− mice (90). IP4 strongly resembles the phosphate head-
group of PI(3,4,5)P3 and therefore it can bind to PH-domain
containing proteins that also bind to PI(3,4,5)P3 (e.g., ITK, AKT)
and perhaps several others (2). In T cells IP4 functions as a second
messenger and regulates Itk membrane recruitment and activa-
tion upon TCR stimulation and therefore it is essential for full
activation of ITK and its effector PLCγ (90). At physiological
concentrations of IP4 in TCR stimulated T cells it promotes ITK
binding to PI(3,4,5)P3, whereas at high IP4 concentrations it com-
petes with PI(3,4,5)P3 for PH-domain binding (2). Because of the
essential role of IP4 in T cell development and function it would
be intriguing to know whether IP4 turnover at in primary T cells is
regulated by SHIP1 5′phosphatase activity. This might be investi-
gated by determining the measuring IP4 levels in SHIP1-deficient
T cells (vs. WT) to provide evidence of negative regulation of
IP4 by SHIP1 in vivo. If this appears to be the case, then it would
then be interesting to test whether the increased IP4 concentration
in SHIP1−/− T cells results in diminished PI(3,4,5)P3 binding of
PH-domain signaling proteins recruited to PI(3,4,5)P3 (e.g., ItK
or AKT) to regulate T cell function.
SHIP2
A close homolog of SHIP1 is the ubiquitously expressed 150 kDa
protein SHIP2. Unlike SHIP1, whose expression is confined to
hematolymphoid cells, osteoblasts (24), and mesenchymal stem
cells (91). SHIP2 is expressed broadly in both hematopoietic and
non-hematopoietic tissues such as brain, skeletal muscle, heart,
liver, and kidney (92, 93). SHIP2 hydrolyzes the 5′ phosphate of
PI(3,4,5)P3 in vitro and in vivo and has also been shown to dephos-
phorylate PI(4,5)P2 in vitro (94, 95). Thus, it may not be restricted
to hydrolysis of the 5′PO4 groups on 3′ PO4-containing poly-
phosphates, PI(3,4,5)P3 and I(1,3,4,5)P4, like its close homolog
SHIP1. SHIP2 is tyrosine phosphorylated upon stimulation with
stem cell factor (SCF), interleukin-3 (IL-3), and granulocyte-
macrophage colony-stimulating factor (GM-CSF), which results
in its association with SHC (src homologous and collagen gene).
Suggesting that SHIP2, similarly to SHIP1, is linked to downstream
signaling events after activation of hematopoietic growth factor
receptors. SHIP2 plays a major role in negatively regulating insulin
signaling in non-immune cells (93). Bruyns et al. reported that
both SHIP1 and SHIP2 are expressed in human T lymphocytes
with only SHIP2 protein levels increased after long-term stimu-
lation of the TCR (96). SHIP2 has also been shown to associate
with the SH3 domain of Tec kinase and inhibit Tec-mediated TCR
signaling (35). However, a physiological role for SHIP2 in T cell
biology and function remains to be demonstrated and defined.
In addition to SHIP1 and SHIP2, eight other 5′ phos-
phatases have been reported; OCRL1 (oculocerebrorenal syn-
drome of Lowe), synaptojanin1, synaptojanin 2, proline rich
inositol poly-phosphate 5-phosphatase (PIPP), 72-5ptase/Type
IV/Inpp5e,SKIP, INPP5B,and 5-phosphatase1. With the exception
of 5-phosphatase1 that hydrolyzes only the soluble inositol phos-
phates Ins(1,4,5)P3 and Ins(1,3,4,5)P4, other phosphatases can
dephosphorylate 5-phosphorylated phosphoinositides including
PtdIns(4,5)P2, PtdIns(3,4,5)P3, PtdIns(3,5)P2, and soluble inos-
itol phosphates although with variable efficiency (95). Some of
these phosphatases are implicated in human diseases, for instance
OCRL1 mutations are associated with Lowe’s syndrome and Dent
2 disease (95, 97), SKIP and 72-5ptase/Type IV/Inpp5e are impli-
cated in insulin signaling and glucose homeostasis while Synap-
togenin1 in mice is required for neuronal function. Overlapping
functions for some of the 5′phosphatases have been reported for
example OCRL1−/− mice do not develop Lowe’s disease since
loss of OCRL1 was compensated by a highly homologous protein
Inpp5b (98). Thus far no immune phenotype has been reported in
any mouse mutant of these other 5′ inositol phosphatases. How-
ever, further studies are merited to rigorously exclude a specific
role in T cell signaling.
PHOSPHATASE AND TENSIN HOMOLOG (PTEN)
Phosphatase and tensin homolog deleted on chromosome 10 was
originally identified as a tumor suppressor gene, which negatively
regulates cell survival and proliferation and is mutated in sev-
eral cancers (99, 100). PTEN germline mutations are associated
with several hereditary disorders characterized by hamartomas
and increased cancer risk such as Cowden syndrome, Bannayan–
Riley–Ruvalcaba syndrome, Proteus syndrome, and Proteus-like
syndrome, collectively classified as PTEN hamartoma tumor syn-
drome (PHTS) (101). PTEN predominantly acts as a 3′ lipid
phosphatase to oppose PI3K signaling by dephosphorylating
PI(3,4,5)P3, a product of PI3K, at its 3′ hydroxyl position to yield
PI(4,5)P2 (102). Other than its 3′ lipid phosphatase activity, PTEN
also possess protein phosphatase activity and has been reported to
dephosphorylate focal adhesion kinase (FAK) by direct binding
(103). Homozygous PTEN−/− knockout mice die early during
embryogenesis, precluding analysis of PTEN role in various adult
tissues and organs in germline mutant mice. However a wide range
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of information has been collected from studies using mice het-
erozygous for PTEN or lacking PTEN in various tissues using
Cre-loxP models (21). Table 1 summarizes the function PTEN in
T cells in different genetic mouse models.
Phosphatase and tensin homolog heterozygous mice show high
tumor incidence, impaired Fas mediated cell death, and develop
autoimmune disorders. T cells from these mice show increased
proliferation, reduced activation induced cell death suggesting an
important role of PTEN in T cell survival and activation (51).
Studies from mice lacking PTEN in T cells revealed an important
role for PTEN in T cell development, function, and homeostasis
(22). Mice lacking PTEN in T cells (LckCre-PTENflox/−) die pre-
maturely due to CD4+ T cell lymphomas and develop symptoms
of autoimmunity like autoantibody production and hypergam-
maglobulinemia. These mice show defective lineage commitment,
altered thymic selection, and impaired peripheral tolerance. T cells
from these mice were hyper-proliferative, secreted increased levels
of Th1/Th2 cytokines, and were autoreactive. Resistance to apop-
tosis, increased AKT and ERK phosphorylation, and increased
Bcl-XL expression were observed in these T cells suggesting a vital
role PTEN in regulation of T cell survival and apoptosis signaling
(22). Hagenbeek et al. further confirmed the role of PTEN in T cell
survival and development by analyzing LckCre-PTENflox/flox mice.
They showed that in the absence of PTEN there is a diminished
requirement for both IL-7R and pre-TCR signaling in T cell devel-
opment and proliferation (52). PTEN deficient CD4+ T cells show
hyper-responsiveness to TCR stimulation without requirement
for co-stimulation signals and are refractory to anergy induc-
tion. Moreover, PTEN−/− T cells show increased AKT and GSK3β
phosphorylation and enhanced IL-2 production upon TCR stim-
ulation. This suggests that by negatively regulating TCR signaling,
PTEN sets a threshold for T cell activation and imposes a require-
ment for co-stimulation and thus regulates T cell anergy (104).
PTEN regulates the response of Tregs to IL-2 and plays a negative
role in IL-2R signaling in Tregs, which normally do not expand
in response to IL-2 alone. However, when Treg cells are deficient
in PTEN they can proliferate upon IL-2 stimulation without the
requirement for TCR stimulation (53). PTEN deficient CD4 T
cells also produce more Th2 cytokines (IL-4, IL-10) in response to
TCR stimulation alone or in combination with CD28 suggesting a
role of PTEN in regulation Th2 cytokine production (105). Thus
PTEN negatively regulates the TCR signaling and the induction
of key cytokines. Thus, efficient and sustained TCR signaling and
cytokine responses by T cells requires down-modulation of PTEN
which occurs following TCR stimulation (106). Further Cbl-b has
been shown to regulate down-modulation of PTEN in response
to TCR/CD28 stimulation by inhibiting PTEN association with
Nedd4, which targets PTEN K13 for K63-linked polyubiquitina-
tion suggesting that multiple pathways may regulate PTEN in the
context to TCR/CD28 stimulation (107).
Studies from various knockout models showed clearly that
PTEN plays an important role as a tumor and autoimmunity
suppressor. However, the mechanistic insights into the relation-
ship of these two functions of PTEN in T cells revealed that these
two functions of PTEN are distinct, context dependent and are
mediated in T cells at different developmental stages. By using
mice with deletion of PTEN in T cells (CD4CrePtenfl/fl), Liu
et al. demonstrated that T cell lymphomas arise in the thymus
whereas autoimmunity was mediated by mature peripheral T cells
(108). Subsequently Soond et al. studied the role of PTEN in
mature CD4 TH cells by using OX40CrePtenflox mice. Contrary
to models of thymocyte-specific PTEN deletion OX40CrePtenflox
mice did not develop lymphomas and autoimmunity even at an
advanced age suggesting that PTEN does not act as a tumor sup-
pressor or repressor of autoimmunity in mature T cells. In fact,
PTEN deficient CD4 TH cells produced increased concentrations
of cytokines and were hyper-proliferative. The authors postulated
that enhanced cytokine production turned PTEN deficient TH cells
into “super-helpers” as enhanced inflammatory, antibacterial, and
anti-tumor responses were observed in OX40crePtenflox mice (54).
Thus contrary to the prevalent view PTEN does not essentially
always function as a tumor suppressor or immune-suppressor
and can also, like SHIP1, have varied functions depending on
cell type, developmental stage of cell, and biological context.
This was further confirmed by a recent study by Locke et al.
by employing a model where PTEN is deleted in post-thymic
T cells. They observed enhanced cytokine production, prolifer-
ation, and activation of post-thymic PTEN deleted T cells. As
observed earlier, these effects were associated with increased AKT
activity. However, CD28 independence and anergy resistance were
not observed (109). Enhanced cytokine production, antibacter-
ial, and anti-tumor responses of PTEN deficient T cells argue
that therapeutic strategies targeting pharmacological inhibition
of PTEN may prove attractive in immunotherapeutic strategies
that require enhanced T effector function. Recently small mol-
ecule inhibitors of PTEN has been identified and used in vivo
without causing prominent toxicity (110, 111). However, further
studies are required to assess the role of these inhibitors on T cell
effector and regulatory functions before considering their use in
immunotherapeutic approaches.
INOSITOL POLY-PHOSPHATE 4-PHOSPHATASE (INPP4)
Inositol poly-phosphate 4-phosphatases are a class of enzymes that
has two isoforms INPP4A and INPP4B, that selectively remove
the phosphate group at position 4 on the inositol ring to con-
vert PI(3,4)P2 to PI(3)P (112). In contrast to INPP4A, which is
predominantly expressed in brain, INPP4B is highly expressed
in skeletal muscle, heart, brain, and pancreas, epithelial cells of
the breast, and prostate glands (113). INPP4A has been shown to
regulate neuroexcitatory cell death whereas INPP4B has emerged
as potent tumor suppressor in breast cancer (114, 115). The
function of the INPP4A and INPP4B phosphatases in immune
cells has not been investigated, although a prominent role for
INPP4B in myeloid-derived osteoclast function and bone remod-
eling has been shown (116). Thus, further investigation of these
4′-phosphatases appears merited and particularly in cell types and
immune contexts where SHIP1 has a positive signaling role (e.g., T
cell survival the gut). Function of inositol phosphatases in T cells
is summarized is Figure 2.
CONCLUDING REMARKS
Consistent with studies implicating class I PI3K in T cell biology,
the inositol phosphatases, SHIP1 and PTEN, have been docu-
mented to be important regulators of PI3K signaling pathway
in T cells. Although SHIP1 and PTEN by dephosphorylating
the PI(3,4,5)P3 negatively regulate PI3K signaling, their in vivo
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FIGURE 2 | Inositol phosphatases inT cell biology. Upon TCR stimulation
PI3K is activated and recruited to the membrane through its SH2 domain
where it phosphorylates its substrate PI(4,5)P2 converting it to PI(3,4,5)P3.
PI(3,4,5)P3 is bound by PH-domain containing proteins such as AKT, PDK1,
BTK, ITK, Vav, and PLCγ triggering secondary signaling cascades and thus T
cell activation, proliferation, survival, and cytokine production. PI3K signaling
is tightly regulated by inositol phosphatases. PI(3,4,5)P3 is a substrate for
three inositol phosphatases, SHIP1/2 and PTEN which hydrolyze PI(3,4,5)P3 to
PI(3,4,)P2 and PI(4,5)P2, respectively. By limiting the cellular pool of the
second messenger PI(3,4,5)P3, PTEN and SHIP play important functions in T
cell development, proliferation, and activation. The SHIP1 product PI(3,4)P2
which can also recruit and activate AKT is dephosphorylated by INPP4.
However the role of these 4-phosphatases in T cell biology has yet to be
determined. AKT, Protein Kinase B; PDK1, phosphoinositide-dependent
kinase-1, PLCγ phospholipase Cγ; ITK, IL-2-inducible T cell kinase) and BTK,
Bruton agammaglobulinemia tyrosine kinase.
functions in this signaling pathway, as reveled by genetic analy-
sis, diverge significantly. SHIP1 appears to be required for the
survival of T cells in vivo, and particularly in the lamina pro-
pria, while PTEN inhibits T cell proliferation and prevents from
lymphoproliferative syndromes. Therefore these phosphatases at
the cellular level provide a fine balance of PI3K signaling nec-
essary for the proper activation and development of T cells in
order to avoid immunopathology. As SHIP1 deficiency has been
shown to promote T cell apoptosis there is a significant poten-
tial for SHIP1 inhibitors, which have already shown promising
results in cancer (43, 73), to be used to target autoreactive T cells
in IBD conditions. Although PTEN has been shown to regulate
CD4 T cell function and tolerance little is known about its role
in other T cell subtypes. Further studies are therefore required to
dissect PTEN signaling in T cells before therapeutic application of
PTEN inhibitors in immunotherapy for cancer could be consid-
ered. In addition, the role of other lipid phosphatases SHIP2 and
INNP4, which regulate the cellular pools of PtdIns (3,4,5)P3 and
PI(3,4)P2, respectively, merit examination in vivo in the coming
years using sophisticated genetic models that enable conditional
and/or inducible ablation of their expression in specific T cell
populations.
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